[go: up one dir, main page]

ATE444308T1 - Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon - Google Patents

Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon

Info

Publication number
ATE444308T1
ATE444308T1 AT03711002T AT03711002T ATE444308T1 AT E444308 T1 ATE444308 T1 AT E444308T1 AT 03711002 T AT03711002 T AT 03711002T AT 03711002 T AT03711002 T AT 03711002T AT E444308 T1 ATE444308 T1 AT E444308T1
Authority
AT
Austria
Prior art keywords
fusion proteins
humanized
specific antibodies
antibodies
disclosed
Prior art date
Application number
AT03711002T
Other languages
English (en)
Inventor
Christoph Renner
Andrew Scott
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE444308T1 publication Critical patent/ATE444308T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03711002T 2002-02-13 2003-02-12 Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon ATE444308T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35583802P 2002-02-13 2002-02-13
PCT/US2003/004243 WO2003068924A2 (en) 2002-02-13 2003-02-12 Fusion proteins of humanized g250 specific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
ATE444308T1 true ATE444308T1 (de) 2009-10-15

Family

ID=27734567

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03711002T ATE444308T1 (de) 2002-02-13 2003-02-12 Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
AT03713430T ATE509032T1 (de) 2002-02-13 2003-02-12 Chimerizierte gm-csf antikörper

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03713430T ATE509032T1 (de) 2002-02-13 2003-02-12 Chimerizierte gm-csf antikörper

Country Status (8)

Country Link
US (5) US7714113B2 (de)
EP (2) EP1530580B1 (de)
JP (1) JP2006500905A (de)
AT (2) ATE444308T1 (de)
AU (2) AU2003217386B2 (de)
DE (1) DE60329489D1 (de)
ES (1) ES2365606T3 (de)
WO (2) WO2003068920A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
EP1530580B1 (de) * 2002-02-13 2011-05-11 Ludwig Institute for Cancer Research Ltd. Chimerizierte gm-csf antikörper
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
JP5408833B2 (ja) * 2002-07-01 2014-02-05 ヴィレックス アクチェンゲゼルシャフト 腎細胞腫を治療するためのＣＧ２５０およびＩＬ−２またはＩＦＮ−αを含有する抗腫瘍剤
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
CA2566950A1 (en) * 2004-07-02 2006-01-12 Wilex Ag Improved adjuvant therapy of g250-expressing tumors
CN101184777B (zh) * 2005-04-18 2013-07-17 安进研发（慕尼黑）股份有限公司 人粒细胞巨噬细胞集落刺激因子的抗体中和剂
ME02059B (me) 2005-05-18 2015-05-20 Morphosys Ag Protutijela protiv gm-csf i njihova upotreba
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
AU2013201228B2 (en) * 2006-02-08 2016-01-21 Eisai, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
CA2641169C (en) 2006-02-08 2017-05-02 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
WO2008063898A2 (en) * 2006-11-08 2008-05-29 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
EP2101780B1 (de) * 2006-11-21 2013-10-09 Kalobios Pharmaceuticals, Inc. Verfahren zur behandlung chronischer entzündungskrankheiten mithilfe eines gm-csf-agonisten
US8398972B2 (en) * 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
CN104043123B (zh) 2007-01-25 2019-08-13 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
EP2134854B1 (de) 2007-03-15 2015-04-15 Ludwig Institute for Cancer Research Ltd. Behandlungsverfahren unter verwendung von egfr-antikörpern und src-inhibitoren und damit verbundene formulierungen
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
US20110044996A1 (en) * 2007-05-23 2011-02-24 Charles Mackay Neutralizing antibodies
WO2009023265A1 (en) 2007-08-14 2009-02-19 Ludwig Institute For Cancer Research Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CN104072613A (zh) * 2007-11-13 2014-10-01 Evec股份有限公司 与hGM-CSF结合的单克隆抗体及包含它的药物组合物
BRPI0907220A2 (pt) * 2008-01-15 2019-02-26 Kalobios Pharmaceuticals, Inc. métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf
JP5608635B2 (ja) * 2008-04-07 2014-10-15 カロバイオス ファーマシューティカルズ インコーポレイティッド 心不全処置のためのｇｍ−ｃｓｆの中和方法
JP5688363B2 (ja) 2008-04-28 2015-03-25 カロバイオス ファーマシューティカルズ インコーポレイティッド 顆粒球−マクロファージコロニー刺激因子に対する抗体
JP2011526792A (ja) * 2008-07-02 2011-10-20 エマージェント プロダクト デベロップメント シアトル， エルエルシー ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質
WO2010009987A2 (en) * 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
CA2734800C (en) * 2008-08-20 2021-02-09 Probiodrug Ag Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe)
WO2010071924A1 (en) 2008-12-22 2010-07-01 The University Of Melbourne Osteoarthritis treatment
JP5674677B2 (ja) 2008-12-22 2015-02-25 ザ ユニバーシティー オブ メルボルンＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｍｅｌｂｏｕｒｎｅ 疼痛治療
WO2010093814A1 (en) 2009-02-11 2010-08-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a gm-csf antagonist
CN102459340A (zh) 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
WO2011040973A2 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
KR102080704B1 (ko) 2010-07-29 2020-02-24 세센 바이오, 아이엔씨. 키메라 il-1 수용체 유형 i 항진제 및 길항제들
US20140234298A1 (en) 2011-07-06 2014-08-21 Morphosys Ag Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
US9526765B2 (en) 2012-02-09 2016-12-27 The Kitasato Institute Delivery of therapeutic agents by a collagen binding protein
CA2881966C (en) 2012-08-24 2020-10-06 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
JP6450364B2 (ja) 2013-03-13 2019-01-09 セセン バイオ， インコーポレイテッド 眼送達のためのキメラサイトカイン製剤
ES2860480T3 (es) 2013-08-30 2021-10-05 Takeda Gmbh Anticuerpos neutralizantes de GM-CSF para su uso en el tratamiento de la artritis reumatoide o como analgésicos
CN106415264A (zh) * 2014-04-04 2017-02-15 奥托泰利克有限责任公司 用于紫杉醇的药代动力学引导给药的监测血浆中的紫杉醇浓度的方法、装置和试剂
US9714953B2 (en) 2014-04-04 2017-07-25 Autotelic Llc Methods, devices, and reagents for monitoring paclitaxel concentration in plasma for pharmacokinetic-guided dosing of paclitaxel
US20160000936A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
EP3474854A4 (de) 2016-06-27 2020-02-19 The Regents of The University of California Krebsbehandlungskombinationen
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
CA3078349A1 (en) 2017-10-02 2019-04-11 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
US12344646B2 (en) 2018-12-13 2025-07-01 Bang DING Antibody-TNF α fusion protein and its preparation and applications
WO2021188409A1 (en) * 2020-03-15 2021-09-23 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
EP0366707A1 (de) 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoklonale antikörper gegen nierenzellen-karzinom
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
WO1994009149A1 (en) * 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
CA2060741A1 (en) * 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5981711A (en) 1992-03-11 1999-11-09 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and hybridomas
US5955075A (en) * 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein
US6027887A (en) 1992-03-11 2000-02-22 Institute Of Virology, Solvak Academy Of Sciences MN gene and protein
US5387676A (en) 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
FR2723462B1 (fr) 1994-08-02 1996-09-06 Thomson Lcd Procede d'adressage optimise d'ecran a cristaux liquides et dispositif pour sa mise en oeuvre
US6406909B1 (en) * 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
US6475749B1 (en) * 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
EP2341075A1 (de) * 2000-03-01 2011-07-06 MedImmune, LLC Anti-rsv-f-protein-antikörper
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
EP1530580B1 (de) * 2002-02-13 2011-05-11 Ludwig Institute for Cancer Research Ltd. Chimerizierte gm-csf antikörper

Also Published As

Publication number Publication date
US20090259027A1 (en) 2009-10-15
WO2003068924A2 (en) 2003-08-21
ATE509032T1 (de) 2011-05-15
EP1507859A2 (de) 2005-02-23
US20100167395A1 (en) 2010-07-01
US20120029172A1 (en) 2012-02-02
EP1507859B1 (de) 2009-09-30
EP1507859A4 (de) 2007-05-30
US20060045876A1 (en) 2006-03-02
US20040053365A1 (en) 2004-03-18
WO2003068920A2 (en) 2003-08-21
ES2365606T3 (es) 2011-10-07
EP1530580A4 (de) 2006-02-01
US7897743B2 (en) 2011-03-01
AU2003217386A1 (en) 2003-09-04
US7381801B2 (en) 2008-06-03
AU2003215188A8 (en) 2003-09-04
WO2003068920A8 (en) 2004-07-29
WO2003068920A3 (en) 2004-07-01
US7714113B2 (en) 2010-05-11
WO2003068920A9 (en) 2004-06-03
AU2003217386B2 (en) 2008-06-26
JP2006500905A (ja) 2006-01-12
AU2003215188A1 (en) 2003-09-04
EP1530580B1 (de) 2011-05-11
DE60329489D1 (de) 2009-11-12
WO2003068924A3 (en) 2004-12-29
EP1530580A2 (de) 2005-05-18

Similar Documents

Publication Publication Date Title
ATE444308T1 (de) Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
ATE541857T1 (de) Optimierte fc-varianten und herstellungsverfahren dafür
WO2005012493A3 (en) Anti-cd19 antibodies
CY1119106T1 (el) Αντισωματα εναντι masp-2
LTPA2016028I1 (lt) Imunoglobulino chimeriniai monomero-dimero hibridai
DK1641483T3 (da) Fusionsproteiner
NZ600584A (en) Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
WO2004013180A3 (en) Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
MY142290A (en) Anti-il-6 antibodies compositions, methods and uses
TW200510459A (en) RG1 antibodies and uses thereof
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
WO2005000901A3 (en) Cd20-specific antibodies and methods of employing same
EA200700917A1 (ru) Способ рефолдинга рекомбинантных антител
WO2006099141A3 (en) Anti-mesothelin antibodies
WO2005042029A3 (en) Psma formulations and uses thereof
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
NZ577828A (en) Human antibodies that bind human il-12 and methods for producing
WO2004003147A3 (en) Cngh0004 polypeptides, antibodies, compositions, methods and uses
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
WO2004093808A3 (en) Novel tumor-associated antigens
WO2004016230A3 (en) Identification of the endothelial receptor for the angiostatin kringle-5
ATE451393T1 (de) Humane anti-idiotypische antikörperfragmente, die her-2/neu ähneln
WO2001004143A3 (en) Prostase vaccine
WO2005047456A3 (en) Anti-idiotype antibodies of the human monoclonal antibody sc-1, and their production and use

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1507859

Country of ref document: EP